title: Natural Killer Cells for Therapy of Leukemia.
abstract: Clinical application of natural killer (NK) cells against leukemia is an area of intense investigation. In human leukocyte antigen-mismatched allogeneic hematopoietic stem cell transplantations (HSCT), alloreactive NK cells exert powerful anti-leukemic activity in preventing relapse in the absence of graft-versus-host disease, particularly in acute myeloid leukemia patients. Adoptive transfer of donor NK cells post-HSCT or in non-transplant scenarios may be superior to the currently widely used unmanipulated donor lymphocyte infusion. This concept could be further improved through transfusion of activated NK cells. Significant progress has been made in good manufacturing practice (GMP)-compliant large-scale production of stimulated effectors. However, inherent limitations remain. These include differing yields and compositions of the end-product due to donor variability and inefficient means for cryopreservation. Moreover, the impact of the various novel activation strategies on NK cell biology and in vivo behavior are barely understood. In contrast, reproduction of the third-party NK-92 drug from a cryostored GMP-compliant master cell bank is straightforward and efficient. Safety for the application of this highly cytotoxic cell line was demonstrated in first clinical trials. This novel 'off-the-shelf' product could become a treatment option for a broad patient population. For specific tumor targeting chimeric-antigen-receptor-engineered NK-92 cells have been designed.
authors.affiliation: Institute for Transfusion Medicine Berlin, German Red Cross Blood Donation Service North-East, Berlin, Germany.
authors.forename: Garnet
authors.initials: G
authors.lastname: Suck
authors.affiliation: Department of Haematology, Singapore General Hospital, Singapore, Singapore.
authors.forename: Yeh Ching
authors.initials: YC
authors.lastname: Linn
authors.affiliation: Institute for Transfusion Medicine Dresden, German Red Cross Blood Donation Service North-East, Dresden, Germany; Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
authors.forename: Torsten
authors.initials: T
authors.lastname: Tonn
keywords: Chimeric antigen receptor; Hematopoietic stem cell transplantation; Killer-cell immunoglobulin-like receptors; NK-92; Natural killer cells